BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:Bring) didn't tiptoe into reinvention. It jumped. The company once known for enzymes and patient studies is now in the grid game, Acquisition of GRID AMe in a business that is rewiring its entire identity. That may sound dramatic, but reinvention it usually is. Investors who just saw a challenged biotech woke up to find the ticker morphing into a player in one of the most valuable races of the decade: keeping the power flowing in an AI-driven world.
GRID AI is not a shiny toy off a company's shelf. It is a platform that has already seen over $50 million in investments since 2019. Your calling card is control, not in theory but in practice. Behind the meter are millions of distributed assets, from rooftop solar arrays to electric vehicle chargers to industrial HVAC systems. If left unmanaged, they behave like a crowd trying to leave a stadium through one door at a time. GRID AI's Dynamic Load Shaping and Aggregation Management platform distributes this amount to outputs that actually work Performance predictable where it normally isn't.
The pivot point may seem crass, but the parallels are revealing. Amp This confirmation is important. Entero's move brings grid you have Entering the public markets looks less like a gamble and more like a calculated jump into a field that is already attracting heavyweight capital. The difference is that Amp currently worth around 2.5 billion US dollars – and the trend is rising.
A strategic pivot into a booming market
The timing is certainly in the queue. Artificial intelligence is consuming energy at a rate that the old grid was never designed for. Goldman Sachs has already warned that global data center consumption could increase by half by 2027 and potentially more than double by 2030. Hyperscalers are building GPU farms that consume electricity like small cities. The problem is not just a question of supply, but also of coordination. Peaks and surges from AI loads can destroy fragile systems, and renewable energy generation isn't behaving politely either. GRID AI is portrayed as a conductor forcing both sides to play in unison.
Entero's move looks less like a pivot and more like a breakout into a larger arena. Biotech's hurdles are legendary: capital intensity, decades-long trials, FDA milestones that arrive slower than the patience of most investors. Energy technology is a completely different area. The problems are immediate, the customers are obvious and easy to reach, and the budgets to solve them are enormous. Entero decided to stop taking the long path of biotechnology and instead take the fast lane into a sector characterized by urgency. This is the realization that progress rewards those willing to be brave.
The price of reinvention can be summed up in one word: control. GRID AI shareholders now own the lion's share of Entero's equity, more than eighty percent on a fully diluted basis, with corresponding influence over the board. Legacy investors endured dilution as part of the transition, but also got a front-row seat to a different story: one that connects to trillion-dollar themes rather than being pigeonholed into a niche pipeline. And only with 1.69 million fully diluted Entero sharesthe free float is small enough that good news can move the stock with outsized impact.
For Entero, this deal turns a routine compliance measure into a stepping stone. A reverse split preserved the Nasdaq listing, but that listing now has new meaning. No longer a capital-intensive biotech company facing lengthy timelines, Entero is emerging as the public gateway for an AI energy platform, a direct channel to capital and visibility without the delays of a traditional IPO.
Implementation will be the value driver
The execution will determine how this story unfolds. Utilities are acting cautiously, regulators are creating additional tension, and scaling across jurisdictions will test GRID AI's adaptability. But none of these hurdles change the course. The network is under pressure, AI workloads are multiplying, and demand response is a market desperate for answers. Companies that can bring order to this chaos not only secure contracts; They will help reshape the design of modern infrastructure.
So the reasoning shines through the noise. Energy demand and renewable volatility are colliding in real time. Proof of value is not theoretical; This is evident in the push to provide more power everywhere, from data centers to neighborhoods. GRID AI provides orchestration in an environment where orchestration is a scarce commodity. This scarcity Is the opportunity.
Ultimately, this is not about giving up one dream for another. It's about relevance, timing and the willingness to bet on another problem that also needs to be solved today. Entero Therapeutics has transformed itself into an energy intelligence vehicle just as AI threatens to bring down the power grid.
GRID AI's unique selling point is that it offers the scarcity and visibility of a Nasdaq listing, giving investors direct access to a market that others follow privately. It is a rare kind of boldness that says revival comes from creating the future, not waiting for it. If the execution matches the vision, Entero's reinvention may be remembered less as a pivot and more as a blueprint.
About GRID AI
GRID AI is a grid edge technology company that provides Dynamic Load Shaping™, DER aggregation and AI-driven orchestration to enable a future-proof, transactive grid. Its aggregation management platform leverages IoT, AI/ML and edge analytics to predict, optimize and distribute flexible demand across millions of devices for utilities, retailers and large energy consumers. www.grid-ai.com
ABOUT ENTRY THERAPEUTICS, INC. (NASDAQ:TOT)
Entero Therapeutics is a publicly traded company on Nasdaq. Entero Therapeutics is a late-stage, clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in gastrointestinal health and include the development of Adrulipase, a recombinant lipase enzyme designed to facilitate the digestion of fats and other nutrients in patients with cystic fibrosis and chronic pancreatitis with exocrine pancreatic insufficiency. Upon completion of the GRID AI acquisition, ENTO intends to continue these prior activities and operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This article was prepared by Hawk Point Media Group, LLC and may contain information, views or opinions regarding Entero Therapeutics, Inc.'s future expectations, plans and prospects that constitute or may constitute forward-looking statements. These statements are not historical facts and are based on assumptions, beliefs and expectations regarding future economic and operating performance. Although Hawk Point Media Group, LLC believes that such statements are made in good faith and based on information available at the time of writing, there can be no assurance that the expectations expressed will prove to be accurate. Entero Therapeutics, Inc. and Hawk Point Media Group, LLC undertake no obligation to update or revise any forward-looking statements, except as required by law.
By their nature, forward-looking statements are subject to risks, uncertainties and factors that could cause actual results to differ materially from those projected. These factors include, but are not limited to, industry conditions, regulatory developments, economic trends and risks identified in Entero Therapeutics, Inc.'s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.
Accuracy and Disclosure Statement: Hawk Point Media Group, LLC (HPM) works with IR Agency, Inc. on a fee-for-service basis to provide press release, editorial, digital media and consulting services. Accordingly, IR Agency, Inc. may engage HPM to create sponsored content relating to public companies during the term of the Agreement. Up to ten thousand dollars of the fee received in U.S. dollars will be used to create and distribute content about Entero Therapeutics, Inc. By virtue of this agreement, such content should be considered sponsored content. The information contained herein is based on sources believed to be reliable, including publicly available records, company disclosures and direct website content, and is accurate to the best of our knowledge at the time of writing. This content is for informational purposes only and should not be construed as investment advice. As of the date of writing, HPM does not own, purchase, sell or trade securities of any covered company and does not hold shares of Entero Therapeutics, Inc. Any reproduction or syndication of this content must include this statement. This disclosure is made in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission's Endorsement Guides and other applicable sponsored investment content regulations.
Contact email for this publication: info@hawkpointmedia.com
SOURCE: Entero Therapeutics
View the original press release on ACCESS Newswire
